{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:01:36Z","timestamp":1784901696969,"version":"3.55.0"},"reference-count":25,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sequel Med Tech","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Randomized controlled trials and real-world studies have demonstrated that automated insulin delivery (AID) systems enhance glycemic control and mitigate hypoglycemia risk in individuals with type 1 diabetes. This study evaluated the safety, effectiveness, and usability of the twiist AID System on glycemic outcomes in adults with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>This 8-week, prospective, single-center, single-arm study included 20 adults with type 1 diabetes. The primary outcome measures were the percent of time spent in established continuous glucose monitoring (CGM) glycemic target ranges at 8 weeks. The primary efficacy outcome was percent time in range (%TIR; 70\u2013180 mg\/dL) at 8 weeks. Secondary outcomes were the change in glucose pre-occlusion detection; the effects of total daily insulin delivery (TDD) on glucose pre- and post-occlusion detection; the effect of Max basal ratio on %TIR; the effect of users\u2019 correction range on %TIR; and change in glycated haemoglobin (HbA1c). Changes in TDD and body weight were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>19 participants completed the study. At 8 weeks, the mean %TIR was 70.3\u00b115.5%. Participants achieved or maintained glycemic targets for all CGM metrics except time above &gt;250 mg\/dL. A total of 67 occlusion events occurred in 15 participants. These events were detected within 30 min of rising glucose. Higher max basal ratio settings were associated with higher %TIR. The %TIR for participants with a correction range &lt;100 mg\/dL was 79.2\u00b113.4% vs 67.2\u00b115.0% for those with a correction range &gt;100 mg\/dL. HbA1c levels decreased (\u22120.4%\u00b10.5%) in participants with baseline HbA1c &gt;7%. A slight increase in TDD (1.3\u00b116.2 U) and a decrease in body weight (\u22120.09\u00b12.9 kg) were observed. No serious adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eight-week use of twiist enabled participants to achieve or maintain established glycemic targets and suggests the system\u2019s ability to detect occlusions before clinically significant glucose rise regardless of TDD. Larger and longer term studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2026-006307","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:05:15Z","timestamp":1784898315000},"page":"e006307","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical utility of the twiist Automated Insulin Delivery System: first study with twiist"],"prefix":"10.1136","volume":"14","author":[{"given":"Adriana","family":"Ruiz","sequence":"first","affiliation":[{"name":"Atlanta Diabetes Associates, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mcdonough","sequence":"additional","affiliation":[{"name":"Atlanta Diabetes Associates, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Snow","sequence":"additional","affiliation":[{"name":"Sequel Med Tech LLC, Manchester, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Bode","sequence":"additional","affiliation":[{"name":"Atlanta Diabetes Associates, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Mitri","sequence":"additional","affiliation":[{"name":"Sequel Med Tech LLC, Manchester, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072406050629000_14.4.e006307.1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S007"},{"key":"2026072406050629000_14.4.e006307.2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s13300-023-01394-5","article-title":"A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems","volume":"14","author":"Peacock","year":"2023","journal-title":"Diabetes Ther"},{"key":"2026072406050629000_14.4.e006307.3","doi-asserted-by":"crossref","unstructured":"Wilcox JH , Gray JC , Cooper NR , et al . 696-P: Insulin Pump Infusion Set Failure (IPISF) Management: T1D Exchange Survey. Diabetes 2021;70. doi:10.2337\/db21-696-P","DOI":"10.2337\/db21-696-P"},{"key":"2026072406050629000_14.4.e006307.4","doi-asserted-by":"publisher","DOI":"10.1177\/1932296820918894"},{"key":"2026072406050629000_14.4.e006307.5","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0548"},{"key":"2026072406050629000_14.4.e006307.6","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0119"},{"key":"2026072406050629000_14.4.e006307.7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1932296816667510","article-title":"Randomized Cross-Over Study Comparing Two Infusion Sets for CSII in Daily Life","volume":"11","author":"Freckmann","year":"2017","journal-title":"J Diabetes Sci Technol"},{"key":"2026072406050629000_14.4.e006307.8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/1932296817753644","article-title":"Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump","volume":"12","author":"Thrasher","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"2026072406050629000_14.4.e006307.9","unstructured":"U.S. Food & Drug Administration . Title 21--Food and Drugs Chapter I--Food and Drug Administration, Department Of Health And Human Services, Subchapter H - Medical Devices, Available: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=880.5730 [Accessed 20 Apr 2024]."},{"key":"2026072406050629000_14.4.e006307.10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/19322968221145731","article-title":"Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review","volume":"17","author":"Zhang","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"2026072406050629000_14.4.e006307.11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1109\/OJEMB.2024.3408092","article-title":"Performance of a Continuous Subcutaneous Insulin Infusion (CSII) Pump With Acoustic Volume and Flow Sensing in Simulated High-Consequence Situations","volume":"5","author":"Butterfield","year":"2024","journal-title":"IEEE Open J Eng Med Biol"},{"key":"2026072406050629000_14.4.e006307.12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0333-9"},{"key":"2026072406050629000_14.4.e006307.13","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"2026072406050629000_14.4.e006307.14","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1581"},{"key":"2026072406050629000_14.4.e006307.15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-025-06366-x","article-title":"One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study","volume":"68","author":"De Meulemeester","year":"2025","journal-title":"Diabetologia"},{"key":"2026072406050629000_14.4.e006307.16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/dia.2023.0578","article-title":"Real-World Evidence of Omnipod\u00ae 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes","volume":"26","author":"Forlenza","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"2026072406050629000_14.4.e006307.17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2337\/dc23-1581","article-title":"Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System","volume":"47","author":"Casta\u00f1eda","year":"2024","journal-title":"Diabetes Care"},{"key":"2026072406050629000_14.4.e006307.18","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0172"},{"key":"2026072406050629000_14.4.e006307.19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/dia.2021.0319","article-title":"Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes","volume":"24","author":"Carlson","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"2026072406050629000_14.4.e006307.20","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.2337\/dc22-2046","article-title":"Safety of Real-life Usage of Advanced Hybrid Closed-Loop System MiniMed 780G in Children With Type 1 Diabetes Younger Than 7 Years Old","volume":"46","author":"Tornese","year":"2023","journal-title":"Diabetes Care"},{"key":"2026072406050629000_14.4.e006307.21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1932296817700545","article-title":"Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block","volume":"11","author":"Klonoff","year":"2017","journal-title":"J Diabetes Sci Technol"},{"key":"2026072406050629000_14.4.e006307.22","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0168"},{"key":"2026072406050629000_14.4.e006307.23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/1932296817750404","article-title":"Occlusion Detection Time in Insulin Pumps at Two Different Basal Rates","volume":"12","author":"Freckmann","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"2026072406050629000_14.4.e006307.24","doi-asserted-by":"crossref","DOI":"10.2337\/db21-696-P","article-title":"696-P: Insulin Pump Infusion Set Failure (IPISF) Management: T1D Exchange Survey","volume":"70","author":"Wilcox","year":"2021","journal-title":"Diabetes"},{"key":"2026072406050629000_14.4.e006307.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.08.015"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2026-006307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:05:17Z","timestamp":1784898317000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2026-006307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjdrc-2026-006307"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2026-006307","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}